递表 | TIL疗法创新药领军企业“君赛生物-B”首次递表,中信证券独家保荐

新浪财经
Dec 18, 2025

来源:市场资讯(来源:弗若斯特沙利文)2025年12月10日,君赛生物首次向港交所递交招股书,拟在香港主板上市,独家保荐人为中信证券。公司是实体瘤创新细胞疗法与创新药开发企业,核心产品GC101有望成为中国首个获批上市的TIL疗法。公司产品尚未实现商业化,2024年净亏损1.64亿元,2025年前三季度净亏损0.98亿元,账上现金仅余0.63亿元。公司是一家致力于实体瘤创新细胞疗法与创新药开发的...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10